drugset / Trial / NCT00113685

Hypertonic Saline With Dextran for Treating Hypovolemic Shock and Severe Brain Injury

NCT00113685 ↗

RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the clinical outcome of patients following blunt traumatic injury with hypovolemic shock, who receive either lactated ringer's solution or hypertonic saline with dextran (HSD) resuscitation; also, to focus specifically on neurologic outcome in patients with brain injury and on the effect of HSD resuscitation on inflammatory cell responsiveness.

Timeline

Start
2003-04
Primary completion
—
Completion
2007-03

Outcome

Missed primary endpoint

paper Intent-to-treat analysis demonstrated no significant difference in ARDS-free survival (hazard ratio, 1.01; 95% confidence interval, 0.63-1.60). PMID 18283138 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Hypertonic Saline-Dextran Solution Other / unclassified 250 ml —
Subject Lactated Ringer's Solution Other / unclassified 250 ml Intravenous